hemp seeds, hearts and prtotein


Hemp is the common name for plants of the entire genus Cannabis.  This term is often used to refer only to Cannabis strains cultivated for   industrial (non-drug) use.

Industrial hemp has many uses, including paper,  textiles, biodegradable plastics, construction,  health food, and fuel.  It is one of the fastest   growing biomasses known and one of the earliest domesticated plants known.  It also runs parallel with the “Green Future” objectives that are becoming increasingly popular. Hemp requires little to no pesticides no herbicides controls erosion of the topsoil, and produces oxygen. Furthermore, hemp can be used to replace many potentially harmful products, such as tree paper (the processing of which uses chlorine bleach, which results in the waste product polychlorinated dibensodioxins, popularly known as dioxins, which are carcinogenic, and contribute to deforestation, cosmetics, and plastics, most of which are petroleum-based and do not decompose easily. The strongest chemical needed to whiten the already light hemp paper is non-toxic hydrogen peroxide.

Cannabis sativa L. subsp. sativa var. sativa is the variety grown for industrial use in Europe, Canada, and elsewhere, while C. sativa subsp. indica generally has poor fiber quality and is primarily used for production of recreational and medicinal drugs. The major difference between the two types of plants is the appearance and the amount of THC secreted in a resinous mixture by epidermal hairs called glandular trichomes. Strains of Cannabis approved for industrial hemp production produce only minute amounts of this psychoactive drug, not enough for any physical or psychological effects. Typically, Hemp contains below 0.3% THC, while Cannabis grown for marijuana can contain anywhere from 6 or 7 % to 20% or even more.

Industrial Hemp is produced in many countries around the world. Major producers include Canada, France, and China. While more hemp is exported to the United States than to any other country, the United States Government does not consistently distinguish between marijuana and the non-psychoactive Cannabis used for industrial and commercial purposes.

What Is CBD?

Cannabidiol — CBD— is a cannabis compound that has significant medical benefits, but does not make people feel “stoned” and can actually counteract the psychoactivity of THC. The fact that CBD-rich hemp doesn’t get one high makes it an appealing treatment option for patients seeking anti-inflamitory, anti-pain, anti-anxiety, anti-psychotic and/or anti-spasm effects without troubling lethargy or dysphoria.

Scientific and clinical studies underscore CBD’s potential as a treatment for a wide range of conditions including arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.

MyCompassion provides educational resources for physicians, patients, and the general public. We respond to inquiries from all over the world. Almost everyone wants to know where to get CBD and how to use it for maximum benefit. After decades in which only high-THC cannabis was available in North America and beyond, CBD-rich strains and products are now accessible to medical users.

On this website, you’ll find cutting-edge information on developments in cannabinoid science and therapeutics, as well as practical information from doctors and patients who are exploring the use of CBD-rich hemp. You will also learn how you can participate in a grassroots, populist effort to harness the curative qualities of CBD-rich hemp.

Here are a few facts about CBD derived from industrial hemp:

  • Agricultural hemp and medical cannabis both come from the Cannabis Sativa L. plant.
  • Agricultural hemp, which is often referred to as “hemp stalk,” grows differently than THC-containing cannabis, and looks similar to bamboo.
  • THC-producing marijuana plants are grown to an average of five feet in height, spaced six to eight feet apart. Agricultural hemp is grown to a height of 10 to 15 feet or more before harvest, placed three to six inches apart.
  • Hemp has little potential to produce high-content THC when pollinated.
  • As long as agricultural hemp plants are pollinated by members of their own crop, the genetics will remain similar with low levels of THC.
  • There is a strong legal argument that production and distribution of CBD oils/products derived from imported raw material industrial hemp is not a violation of the Controlled Substances Act (CSA); in fact, one Colorado law firm has published a written opinion making the case.



State Program Name and Statutory Language (year) Patient Registry or ID cards Specifies Conditions Recognizes Patients from other states Defintion of Products Allowed Allows for Legal Defense Allowed for Minors
Alabama  SB 174 “Carly’s Law”(Act 2014-277) Allows University of Alabama Birmingham to conduct effectiveness research using low-THC products for treating seizure disorders for up to 5 years.Not operational as of April, 2015. Yes, debilitating epileptic conditions or life-threatening seizures. No Extracts that are low THC= below 3% THC Yes Yes
Florida Compassionate Medical Cannabis Act of 2014 CS for SB 1030 (2014)Patient treatment information and outcomes will be collected and used for intractable childhood epilepsy research Yes Yes, cancer, medical condition or seizure disorders that chronically produces symptoms that can be alleviated by low-THC products No Cannabis with low THC= below .8% THC and above 10% CBD by weight Yes, with approval from 2 doctors
Georgia HB 1 (2015) (signed by governor 4/16/15) Yes Yes, end stage cancer, ALS, MS, seizure disorders, Crohn’s, mitochondrial disease, Parkinson’s, Sickle Cell disease No Cannabis oils with low THC= below 5% THC and at least an equal amount of CDB. Yes Yes
Iowa SF 2360, Medical Cannabidiol Act of 2014 (Effective 7/1/14) Yes Yes, intractable epilepsy No “Cannabidiol- a non-psychoactive cannabinoid” that contains below 3% THC, no more than 32 oz, and essentially free from plant material. Yes Yes
 Idaho- VETOED BY GOVERNOR SB 1146 (VETOED by governor 4/16/15) No The possessor has, or is a parent or guardian of a person that has, cancer, amyotrophic lateral sclerosis, seizure disorders, multiple sclerosis, Crohn’s disease, mitochondrial disease, fibroymyalgia, Parkinson’s disease or sickle cell disease; No Is composed of no more than three-tenths percent (0.3%) 5 tetrahydrocannabidiol by weight; 6 (ii) Is composed of at least fifteen (15) times more cannabidiol 7 than tetrahydrocannabidiol by weight; and 8 (iii) Contains no other psychoactive substance. Yes Yes
Kentucky SB 124 (2014) Clara Madeline Gilliam ActExempt cannabidiol from the definition of marijuana and allows it to be administerd by a public university or school of medicine in Kentucky for clinical trial or expanded access program approved by the FDA. No Intractable seizure disorders No No, only “cannabidiol”.
Mississippi HB 1231 “Harper Grace’s Law” 2014 Yes, debilitating epileptic condition or related illness No “CBD oil” – processed cannabis plant extract, oil or resin that contains more than 15% cannabidiol, or a dilution of the resin that contains at least 50 milligrams of cannabidiol (CBD) per milliliter, but not more than one-half of one percent (0.5%) of tetrahydrocannabinol (THC) Yes, if an an authorized patient or guardia Yes
Missouri HB 2238 (2014) Yes Yes, intractable epilepsy that has not responded to three or more other treatment options. No “Hemp extracts” equal or less than .3% THC and at least 5% CBD by weight. Yes Yes
North Carolina HB 1220 (2014) Epilepsy Alternative Treatment Act- Pilot Study Yes Yes, intractable epilepsy No “Hemp extracts” with less than three-tenths of one percent (0.3%) tetrahydrocannabinol (THC) by weight.Is composed of at least ten percent (10%) cannabidiol by weight.
Contains no other psychoactive substance.
Yes Yes
Oklahoma  HB 2154 (2015) Yes People under 18 (minors) Minors with Lennox-Gastaut Syndrome, Dravet Syndrome, or other severe epilepsy that is not adequately treated by traditional medical therapies No A preparation of cannabis with no more than .3% THC in liquid form. Yes Yes, only allowed for minors
South Carolina  SB 1035 (2014) Medical Cannabis Therapeutic Treatment Act- Julian’s Law Yes Lennox-Gastaut Syndrome, Dravet Syndrome, also known as severe myoclonic epilepsy of infancy, or any other form of refractory epilepsy that is not adequately treated by traditional medical therapies. No Cannabidiol or derivative of marijuana that contains 0.9% THC and over 15% CBD, or least 98 percent cannabidiol (CBD) and not more than 0.90% tetrahydrocannabinol (THC) by volume that has been extracted from marijuana or synthesized in a laboratory Yes Yes
Tennessee SB 2531(2014)
Creates a four-year study of high CBD/low THC marijuana at TN Tech Univ.
Researchers need to track patient information and outcomes Yes, intractable seisure conditions. No “Cannabis oil” with less than .9% THC as part of a clinical research study
Texas SB 339 (2015)
Texas Compassionate Use Act
Yes Yes, intractable epilepsy. No “Low-THC Cannabis” with not more than 0.5 percent by weight of tetrahydrocannabinols; and not less than 10 percent by weight of cannabidiol Yes Yes
Utah HB 105 (2014) Hemp Extract Registration Act Yes Yes, intractable epilepsy that hasn’t responded to three or more treatment options suggested by neurologist No “Hemp extracts” with less than .3% THC by weight and at least 15% CBD by weight and contains no other psychoactive substances Yes Yes
Virginia HB 1445 No Intractable epilepsy. No. Cannabis oils with at least 15% CBD or THC-A and no more than 5% THC. Yes Yes
Wisconsin AB 726 (2013 Act 267) No Seizure disorders Exception to the definition of prohibited THC by state law, allows for possession of “cannabidiol in a form without a psychoactive effect.”  THC or CBD levels are not defined. No Yes